Acute Myelogenus Leukemia (AML)

Acute Myelogenus Leukemia (AML) is a rapidly advancing disease characterized by the clonal expansion of myeloid precursors in the bone marrow and consequential displacement of normal hematopoietic cells.


Molecular Assays:

PML-RARa: Acute Promyelocytic Leukemia (APL) accounts for 10-15% of Acute Myelogenus Leukemia (AML) and is one of the most curable forms of leukemia with good sensitivity to all-trans retinoic acid (ATRA). Nearly all APL cases are characterized by the presence of the PML-RARa t(15;17) fusion gene transcript which is required for ATRA treatment response. Researchers have identified the utility of measuring PML-RARa transcripts to aid in the classification of APL, predicting treatment response, and monitoring minimal residual disease (MRD).1,2


FISH Assays:

ERG-BA: In AML, ERG function is deregulated due to a fusion with FUS/TLS resulting in the expression of a FUS–ERG fusion protein. Results suggest that FUS–ERG acts as a transcriptional repressor of the retinoic acid signaling pathway.3

Polysomy 8: Studies have shown that polysomy 8 in AML, MDS, and MPD are characterized by a high incidence of secondary diseases, myelomonocytic or monocytic involvement in AML and poor overall survival.4

Order FISH Probes


    1. Cull EH, Altman JK. Contemporary Treatment of APL. Current hematologic malignancy reports. 2014;9(2):193-201. doi:10.1007/s11899-014-0205-6.
    2. Lo-Coco F, Cicconi L. History of Acute Promyelocytic Leukemia: A Tale of Endless Revolution. Mediterranean Journal of Hematology and Infectious Diseases. 2011;3(1):e2011067. doi:10.4084/MJHID.2011.067.
    3. Sotoca AM, Prange KH, Reijnders B, Mandoli A, Nguyen LN, Stunnenberg HG,Martens JH. The oncofusion protein FUS-ERG targets key hematopoietic regulators and modulates the all-trans retinoic acid signaling pathway in t(16;21) acute myeloid leukemia. Oncogene. 2016 Apr 14;35(15):1965-76. doi: 10.1038/onc.2015.261. Epub 2015 Jul 6. PubMed PMID: 26148230; PubMed Central PMCID: PMC4833872.
    4. Beyer V, Mühlematter D, Parlier V, Cabrol C, Bougeon-Mamin S, Solenthaler M,Tobler A, Pugin P, Gregor M, Hitz F, Hess U, Chapuis B, Laurencet F, Schanz U,Schmidt PM, van Melle G, Jotterand M. Polysomy 8 defines a clinico-cytogenetic entity representing a subset of myeloid hematologic malignancies associated with a poor prognosis: report on a cohort of 12 patients and review of 105 published cases. Cancer Genet Cytogenet. 2005 Jul 15;160(2):97-119. Review. PubMed PMID:15993266.